Drug intelligence / Profile preview

epoetin alfa + iron derisomaltose

Development stage
Phase 4
Lead developer
Amgen
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous, Subcutaneous
01

Overview

Epoetin alfa + iron derisomaltose is a combination therapy used primarily to treat anemia, especially in patients with chronic kidney disease or those undergoing chemotherapy. Epoetin alfa is a recombinant form of human erythropoietin, a glycoprotein hormone that stimulates the bone marrow to produce red blood cells. Iron derisomaltose (also known as ferric derisomaltose) is an intravenous iron preparation that replenishes body iron stores necessary for effective erythropoiesis. The combination addresses both insufficient endogenous erythropoietin and depleted iron stores, which are common causes of anemia in these populations. Clinical studies have shown that combining epoetin treatment with intravenous iron supplementation can improve hemoglobin response rates compared to increasing the dose of epoetin alone. This approach reduces the need for blood transfusions and may lower overall doses of erythropoiesis-stimulating agents.

Brand names
Monoferric + EPIAO
Other names
Ferric Derisomaltose + Epoetin AlfaHematoboost protocol
02

Targets

Beyond the preview

Go deeper on epoetin alfa + iron derisomaltose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on epoetin alfa + iron derisomaltose.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call